Section 2: Selection, Procurement and Distribution 2021
DOI: 10.1136/ejhpharm-2021-eahpconf.14
|View full text |Cite
|
Sign up to set email alerts
|

2SPD-031 Subgroup analysis about efficacy of early use of remdesivir in COVID-19

Abstract: Conclusion and relevance DOR would be beneficial in those patients with CNS disorders due to EFV and high viral load (>100 000 copies) or in polymedicated patients because of the lower profile of interactions. In the remaining cases, there are alternatives already available in the hospital (following recommendations of the GESIDA guidelines).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 0 publications
0
0
0
Order By: Relevance